



# **Therapeutic Goods (Standard for Medicinal Cannabis) (TGO 93) Amendment Order (No. 2) 2022**

---

I, Tracey Duffy, as delegate of the Minister for Health and Aged Care, make the following order.

Dated 2 December 2022

Tracey Duffy  
First Assistant Secretary  
Medical Devices and Product Quality Division  
Health Products Regulation Group  
Department of Health and Aged Care

---



---

# Contents

1 Name.....	1
2 Commencement .....	1
3 Authority.....	1
4 Schedules.....	1
<b>Schedule 1—Amendments</b>	<b>2</b>
<i>Therapeutic Goods (Standard for Medicinal Cannabis) (TGO 93) Order 2017</i>	2



---

## 1 Name

This instrument is the *Therapeutic Goods (Standard for Medicinal Cannabis) (TGO 93) Amendment Order (No. 2) 2022*.

## 2 Commencement

- (1) Each provision of this instrument specified in column 1 of the table commences, or is taken to have commenced, in accordance with column 2 of the table. Any other statement in column 2 has effect according to its terms.

Commencement information		
Column 1	Column 2	Column 3
Provisions	Commencement	Date/Details
1. The whole of this instrument	The day after this instrument is registered.	

Note: This table relates only to the provisions of this instrument as originally made. It will not be amended to deal with any later amendments of this instrument.

- (2) Any information in column 3 of the table is not part of this instrument. Information may be inserted in this column, or information in it may be edited, in any published version of this instrument.

## 3 Authority

This instrument is made under section 10 of the *Therapeutic Goods Act 1989*.

## 4 Schedules

Each instrument that is specified in a Schedule to this instrument is amended or repealed as set out in the applicable items in the Schedule concerned, and any other item in a Schedule to this instrument has effect according to its terms.

---

## Schedule 1—Amendments

### *Therapeutic Goods (Standard for Medicinal Cannabis) (TGO 93) Order 2017*

#### 1 Subsection 4(1)

Insert:

*Medsafe* means the New Zealand Medicines and Medical Devices Safety Authority within the New Zealand Ministry of Health.

*New Zealand Code of GMP* means the document *New Zealand Code of Good Manufacturing Practice for Manufacture and Distribution of Therapeutic Goods*, published by Medsafe, as in force or existing from time to time.

#### 2 Subsection 13(1)

Omit “used as starting material in the manufacture of another medicinal cannabis product.”, substitute:

for use as starting material in the manufacture of another medicinal cannabis product manufactured in accordance with:

- (c) subsections (2) and (3); or
- (d) a licence under Part 3-3 of the Act.

#### 3 At the end of subsection 13(2)

Add:

- ; (g) the New Zealand Code of GMP.

#### 4 After paragraph 13(3)(e)

Insert:

- (ea) for a medicinal cannabis product manufactured in New Zealand—  
one of the following:
  - (i) a valid Licence to Manufacture Medicines issued under the *Medicines Act 1981* (NZ), as in force or existing from time to time;
  - (ii) a valid certificate of good manufacturing practice issued to the manufacturer of the product by Medsafe;
  - (iii) written confirmation from the Therapeutic Goods Administration that the manufacturing site operates in accordance with the PIC/S Guide to GMP;

#### 5 Subsection 13(4)

After “certificate”, insert “, licence”.

---

## **6 Section 14**

Repeal the section, substitute:

### **14 Child-resistant packaging**

- (1) This section does not apply to a medicinal cannabis product that is:
  - (a) plant material; or
  - (b) mentioned in section 7 of TGO 95.
- (2) A medicinal cannabis product must comply with the requirements specified in the following sections of TGO 95:
  - (a) section 8 (general requirements); and
  - (b) where the product is in a reclosable package—section 9 (reclosable packages); and
  - (c) where the product is in a non-reclosable package—section 10 (non-reclosable packages).

### **7 Subsection 15(1)**

After “product”, insert “that is a finished product”.

### **8 Paragraph 15(2)(f)**

Omit “stated as the anhydrous form”.

### **9 Subparagraph 15(2)(g)(i)**

Omit “essential”.

### **10 Section 16**

Omit “in oral dosage form”, substitute “that is in oral dosage form or for administration by inhalation”.

### **11 Clause 2 of Schedule 1 (table item 3, column 3)**

Omit “2.4.8”, substitute “2.4.27”.